A new study shows how an anticancer drug triggers an “outside in” signal that gets it sucked into a cancer cell.
ESMO 2023: Mirati’s Krazati and immuno-oncology combo to shape first-line NSCLC – Pharmaceutical Technology
In NSCLC, up to 30% of patients are carrying any form of KRAS mutation. Image: Nemes Laszlo via Shutterstock. At the European Society of Medical
October 23, 2023